Navamedic (NAVA) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached NOK 132 million, up 9.2% year-over-year, driven by strong growth in Prescription Drugs and Hospital segments.

• Gross margin improved to 40.7% from 38.7% in Q1 2024, with EBITDA rising to NOK 12.8 million from NOK 8.5 million.

• Net profit was negative NOK 7.5 million, mainly due to negative net financial items related to market value changes and interest payments.

• Strategic focus shifted toward growth of main brands, own products, and out-licensing, with ambitions to reach NOK 1 billion in revenue and at least 15% EBITDA margin.

• Renewal of exclusive Imdur® rights for eight years and successful launches in antibiotics and consumer health support future growth.

Financial highlights

• Revenue for Q1 2025: NOK 132.0 million (+9.2% YoY); gross margin: 40.7% (vs. 38.7% in Q1 2024).

• EBITDA: NOK 12.8 million (vs. NOK 8.5 million in Q1 2024); EBITDA margin: 9.7%.

• EBIT reached NOK 9.1 million, up from NOK 4.9 million in Q1 2024.

• Net profit: negative NOK 7.5 million; profit before tax: negative NOK 1.8 million.

• Cash at period end: NOK 40.3 million; net cash flow from operations: NOK 9.2 million.

Outlook and guidance

• Focus on expanding main brands, launching new products, and increasing profitability.

• Ambition to become a NOK 1 billion revenue company with at least 15% EBITDA margin.

• Continued growth expected through value-adding M&A and market expansion of own products.